## Jan Freijer

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/876924/publications.pdf

Version: 2024-02-01

361296 315616 1,459 45 20 38 h-index citations g-index papers 45 45 45 1925 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Oxycodone Effect on Pupil Constriction in Recreational Opioid Users: A Pharmacokinetic/Pharmacodynamic Meta-Analysis Approach. Clinical Pharmacokinetics, 2021, 60, 785-794.	1.6	3
2	Population Pharmacokinetics of Tapentadol in Children from Birth to <18 Years Old. Journal of Pain Research, 2020, Volume 13, 3107-3123.	0.8	6
3	Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population. Journal of Pain Research, 2019, Volume 12, 2835-2850.	0.8	8
4	Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration. Journal of Hepatology, 2019, 71, 594-602.	1.8	23
5	Response to letter to the editor from Dr. Mahmood. Journal of Clinical Pharmacology, 2015, 55, 721-721.	1.0	O
6	Population Pharmacokinetic Model of THC Integrates Oral, Intravenous, and Pulmonary Dosing and Characterizes Short- and Long-term Pharmacokinetics. Clinical Pharmacokinetics, 2015, 54, 209-219.	1.6	57
7	Optimizing the glutamatergic challenge model for psychosis, using S(+)-ketamine to induce psychomimetic symptoms in healthy volunteers. Journal of Psychopharmacology, 2015, 29, 401-413.	2.0	22
8	Predicting the "First dose in children―of CYP3Aâ€metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7â€CYP3A4 switch at young ages. Journal of Clinical Pharmacology, 2014, 54, 1006-1015.	1.0	32
9	Profiling the subjective effects of Δ <sup>9</sup> â€ŧetrahydrocannabinol using visual analogue scales. International Journal of Methods in Psychiatric Research, 2014, 23, 245-256.	1.1	16
10	Monitoring Prednisolone and Prednisone in Saliva. Therapeutic Drug Monitoring, 2013, 35, 485-492.	1.0	10
11	Pharmacokinetics and Pharmacodynamics of Orally Administered Clonidine: A Model-Based Approach. Hormone Research in Paediatrics, 2013, 79, 300-309.	0.8	10
12	First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 195-203.	0.8	54
13	Novel Δ <sup>9</sup> â€ŧetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects. British Journal of Clinical Pharmacology, 2012, 74, 42-53.	1.1	64
14	A Semiphysiological Population Model for Prediction of the Pharmacokinetics of Drugs under Liver and Renal Disease Conditions. Drug Metabolism and Disposition, 2011, 39, 1278-1287.	1.7	22
15	An example of optimal phase II design for exposure response modelling. Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37, 475-491.	0.8	4
16	Effect of altered AGP plasma binding on heart rate changes by S(â^')â€propranolol in rats using mechanismâ€based estimations of in vivo receptor affinity (KB,vivo). Journal of Pharmaceutical Sciences, 2010, 99, 2511-2520.	1.6	7
17	Risk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to Humans. Clinical Pharmacokinetics, 2010, 49, 619-632.	1.6	10
18	Influence of Plasma Protein Binding on Pharmacodynamics: Estimation of In Vivo Receptor Affinities of β Blockers Using a New Mechanism-Based PK–PD Modelling Approach. Journal of Pharmaceutical Sciences, 2009, 98, 3816-3828.	1.6	17

#	Article	IF	Citations
19	Pharmacokinetic Modeling of Non-Linear Brain Distribution of Fluvoxamine in the Rat. Pharmaceutical Research, 2008, 25, 792-804.	1.7	25
20	Pharmacokinetic–pharmacodynamic modelling of fluvoxamine 5â€HT transporter occupancy in rat frontal cortex. British Journal of Pharmacology, 2008, 154, 1369-1378.	2.7	11
21	Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex. European Journal of Pharmaceutical Sciences, 2008, 33, 217-229.	1.9	10
22	Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: The role of complex biophase distribution kinetics. European Journal of Pharmaceutical Sciences, 2008, 34, 149-163.	1.9	28
23	Mechanism-Based Pharmacodynamic Modeling of S( $\hat{a}\in$ ")-Atenolol: Estimation of in Vivo Affinity for the $\hat{l}^2$ 1-Adrenoceptor with an Agonist-Antagonist Interaction Model. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 1234-1242.	1.3	6
24	Pharmacokinetic-pharmacodynamic modelling of S (â^')-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint. British Journal of Pharmacology, 2007, 151, 356-366.	2.7	18
25	Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. British Journal of Pharmacology, 2007, 151, 701-712.	2.7	51
26	Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG. British Journal of Pharmacology, 2007, 151, 713-720.	2.7	23
27	Population pharmacokinetic model of fluvoxamine in rats: Utility for application in animal behavioral studies. European Journal of Pharmaceutical Sciences, 2007, 30, 45-55.	1.9	12
28	Pharmacokinetic–pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. European Journal of Pharmaceutical Sciences, 2007, 32, 200-208.	1.9	5
29	Application of the Convection–Dispersion Equation to Modelling Oral Drug Absorption. Bulletin of Mathematical Biology, 2007, 69, 181-195.	0.9	5
30	Disease System Analysis: Basic Disease Progression Models in Degenerative Disease. Pharmaceutical Research, 2005, 22, 1038-1049.	1.7	88
31	Dioxins, dioxin-like PCBs and non-dioxin-like PCBs in foodstuffs: occurrence and dietary intake in The Netherlands. Toxicology Letters, 2004, 151, 51-61.	0.4	239
32	Analysis of Lobar Differences in Particle Deposition in the Human Lung. Inhalation Toxicology, 2003, 15, 1-21.	0.8	51
33	Particle size-dependent total mass deposition in lungs determines inhalation toxicity of cadmium chloride aerosols in rats. Application of a multiple path dosimetry model. Archives of Toxicology, 2002, 76, 277-286.	1.9	101
34	A model for the effect on health of repeated exposure to ozone. Environmental Modelling and Software, 2002, 17, 553-562.	1.9	18
35	Risk Assessment of Deoxynivalenol in Food: Concentration Limits, Exposure and Effects. Advances in Experimental Medicine and Biology, 2002, 504, 235-248.	0.8	45
36	Modeling the Gas Diffusion Coefficient in Analogy to Electrical Conductivity Using a Capillary Model. Soil Science Society of America Journal, 2000, 64, 527-532.	1.2	13

#	Article	IF	CITATIONS
37	Analytical solutions of the convection–dispersion equation applied to transport of pesticides in soil columns. Environmental Modelling and Software, 1998, 13, 139-149.	1.9	9
38	Modelling exposure of the Dutch population to air pollution. Journal of Hazardous Materials, 1998, 61, 107-114.	6.5	13
39	Relation between Bioavailability and Fuel Oil Hydrocarbon Composition in Contaminated Soils. Environmental Science & Technology, 1997, 31, 771-775.	4.6	106
40	Adapted Fick's Law Applied to Soil Respiration. Water Resources Research, 1996, 32, 791-800.	1.7	36
41	Mineralization of Hydrocarbons in Soils under Decreasing Oxygen Availability. Journal of Environmental Quality, 1996, 25, 296-304.	1.0	15
42	Assessing mineralization rates of petroleum hydrocarbons in soils in relation to environmental factors and experimental scale. Biodegradation, 1996, 7, 487-500.	1.5	33
43	Calibration of Jointed Tube Model for the Gas Diffusion Coefficient in Soils. Soil Science Society of America Journal, 1994, 58, 1067-1076.	1.2	65
44	The application of TDR in laboratory column experiments. Soil and Tillage Research, 1993, 6, 261-272.	0.4	10
45	A comparison of field methods for measuring soil carbon dioxide evolution: Experiments and simulation. Plant and Soil, 1991, 135, 133-142.	1.8	58